Daly Richard J purchased $99K of AQST

Daly Richard J purchased 28,025 shares of Aquestive Therapeutics, Inc. (AQST) at an average of $3.54 ($3.53–$3.54) across 2 trades on 2026-11-10.

Original reporting
SEC EDGAR · Daly Richard J
Published Nov 12, 2026, 4:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 5:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AQST
Bullish
medium confidence
Mentioned
$AQST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AQSTBullishLow
01

Why it matters

Director-level buying, though modest, may be interpreted as confidence in upcoming developments.

02

Market read

A routine insider purchase with limited material impact; primarily of interest to short‑term traders monitoring insider activity.

03

What to watch

Potential upcoming clinical data or partnership not disclosed could be the real driver behind the purchase.

Relevance 4/10Novelty 4/10Timing: post‑market filing

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$AQSTBullishMedium confidence
Context

Director Daly Richard J bought 28,025 shares for $99,330, increasing his stake to 28,025 shares.

Expected impact

potential modest upside pressure as market prices in insider buying

Evidence & confidence

The purchase is small relative to market cap, but director-level buying is viewed positively by traders.

Market effects

Minimal impact on the biotech sector; only a single insider transaction.

No regional effect; confined to AQST shareholders.

Low global relevance.

Counterpoint

The purchase is too small to affect price; could be routine portfolio rebalancing.

Key entities

  • Aquestive Therapeutics, Inc.

    Biopharma company developing treatments for neurological disorders.

  • Daly Richard J

    Director of AQST who executed the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.